ClinicalTrials.gg
Status unknownNCT00944502Updated Jul 24, 2009

To Evaluate the Efficacy and Tolerability of the Use of Vitatonus Dexa Compared to Dexamethasone in Patients With Neuralgia of Various Origins

A Phase 3 interventional study of Dexamethasone in Neuralgia, sponsored by Bunker Industria Farmaceutica Ltda.. Status unknown at 1 site in Brazil. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2009-07-24.

Sponsored by Bunker Industria Farmaceutica Ltda. · Phase 3, Interventional, and Treatment

How we know

The sponsor has not verified this record recently (last verified Jul 2009), so the status shown — last known as Not yet recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
104
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 21 studies in Neuralgia with a site in Brazil — 3 open to participants now, 4 under way, 2 of them phase 3. Neuralgia · Brazil.

Planned enrollment
9th of 21
104 · median 80
Started
2009
the only one that year
Phase 3
8 of 21
2 open now
Registered
2nd of 21
by date
Lead sponsor
1 of 21
Bunker Industria Farmaceutica Ltda.

Among the 21 studies in Neuralgia with a site in Brazil, this one is the 9th largest by planned enrollment, is the only one that started in 2009, is one of 8 in phase 3, and was the 2nd registered.

Neuralgia

1,103 studies on the registry are indexed under Neuralgia; 243 are open to participants now.

Browse Neuralgia studies →

Open to participants now

3 of the 21 studies in Neuralgia with a site in Brazil are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →

Who these studies take

Of the 154 Neuralgia studies recruiting now, 78 (51%) set no upper age limit and 44 (29%) stop at 75 or younger; 8 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Neuralgia with a site in Brazil, or all of them as a file.
02

Study summary

To evaluate the efficacy and tolerability of Vitatonus Dexa compared with dexamethasone in the signs and symptoms of neuralgia of various origins.

Clinical study, randomized prospective and random in nature, with a patients diagnosed with neuralgia of diverse origin.

Patients will be include in sufficient quantity to achieve the minimum of 104 evaluable patients.

03

Conditions studied

  • Neuralgia

Browse trials for

Keywords

  • Neuralgy
  • Dexamethasone
  • Complex Vitamins
  • Injection
  • Symptoms of neuralgy of various origins
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients who consent to participate in the study by signing the ICF;
  2. Patients of any ethnic group of both sexs aged over 18 years;
  3. Patients with clinical diagnosis of neuralgia of various origins.
  4. Patients who present scores on the Visual Analogue Scale (VAS) greater than or equal to 4 for PAIN.

Exclusion criteria

Exclusion Criteria:

  1. Patients with known to lidocaine and thiamine or any component of the formula;
  2. Pregnant women and nursing mothers;
  3. Hypertensive or cardiac patients;
  4. Patients with history of ulcers in the stomach or duodenum, diabetes mellitus or severe infections;
  5. Patients who use levodopa, salicylates, colchicine, aminoglycosides, chloramphenicol, anticonvusivantes or potassium supplement.
  6. Patient with a history of alcohol or use illicit drugs;
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
104 participants (estimated)

Study arms

  • Experimental
    Dexamethasone and complex vitamins

    Group A: Vitatonus dexa injectable: 1 ampoule intramuscularly every 3 days for 10 days. Group B: Vitatonus DEXA tablet: 1 tablet orally every 8 hours for 10 days.

    Drug: Dexamethasone

  • Active comparator
    Dexamethasone

    Group C: Dexamethasone Injectable: 1 ampoule intramuscularly every 3 days for 10 days. Group D: Dexamethasone tablet: 1 tablet orally every 8 hours for 10 days.

    Drug: Dexamethasone

Interventions

  • Group A: Vitatonus DEXA injectable: 1 ampoule intramuscularly every 3 days for 10 days. Group B: Vitatonus DEXA tablets: 1 tablet orally every 8 hours for 10 days. Group C: Dexamethasone Injectable: 1 ampoule intramuscularly every 3 days for 10 days. Group D: Dexamethasone tablets: 1 tablet orally every 8 hours for 10 days.

    Also known as: Vitatonus dexa tablest, Vitatonus Dexa Injectable

06

What researchers measure

Primary outcomes

  1. Observation of adverse events related to medication. The causality of adverse events concerning the use of medication will be given after applying the Naranjo Algorythm

    Time frame: Ten days

Secondary outcomes

  1. Efficacy evaluation Likert scale and Visual Analogue

    Time frame: Ten days

07

Study locations

1 site
  • Faculdade de Medicina do ABC
    Santo André, São Paulo 09060650, Brazil
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2009, a primary completion of Nov 2009 and a completion of Dec 2009. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 22, 2009
First posted
Jul 23, 2009
Start
Oct 2009
Primary completionEst.
Nov 2009
CompletionEst.
Dec 2009
Last update
Jul 24, 2009
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 24, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00944502
Lead sponsor
Bunker Industria Farmaceutica Ltda.
First posted
Jul 23, 2009
Start date
Oct 2009
Primary completion
Nov 2009 (estimated)
Completion
Dec 2009 (estimated)
Last update
Jul 24, 2009

Study contacts

Rosa Hasan
principal investigator · Faculdade de Medicina do ABC

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jul 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dexamethasone

Start the discussion